Early Trial Shows Drug Can Curb Ewing’s Sarcoma Growth
An early study of the drug figitumumab has found that in some patients it can curb the growth of Ewing’s sarcoma – a cancer which affects mainly teenage boys. The study was conduted by The Institute of Cancer Research and The Royal Marsden Hospital, and funded by Pfizer, who developed the drug. The promising results have led to the drug’s progression to a Phase II trial in patients with Ewing’s sarcoma.
For the full story, Click Here
- Argenta Discovery begins the phase II trial of ADC4022
- Stalevo has higher efficacy in Parkinson’s disease than the current therapy
- FDA approves hGH needle-free injection by Teva
- Watson Pharmaceuticals’ arm gets nod from U.S. FDA for Azurette Tablets
